Tags: buprenorphineoverdoseopioidthyroid diseasehypertension
| Profile | Contacts | Recent Articles on Subject | |
|---|---|---|---|
| 1 | Aislinn Antrim, Assistant Managing Editor Pharmacy Times Journalist at Pharmacy Times. UNC graduate. | ||
| 2 | Meagan Parrish Pharma Voice Senior editor @industrydive.
Pharma world follower. Wisconsin, USA | Spravato is just the beginning in a new wave of depression meds - about 1 month ago | |
| 3 | Rick Lange, MD, Texas Tech; Elizabeth Tracey MedPage Today Texas Tech University System, advancing higher education and health care. Lubbock, Texas | ||
| 4 | Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois | More evidence on GLP-1s and opioid addiction - 2 months ago | |
| 5 | Emily Olsen Healthcare Dive Reporter at Healthcare Dive. Loyola, Medill alum. Chicago, Illinois | ||
| 6 | MedPage Today Staff MedPage Today Explains healthcare complexities. Not endorsements. New York, New York | Which GLP-1 Drug Was Tied to a Signal of Suicidal Thoughts? - 4 months ago | |
| 7 | Kathleen Kenny, PharmD, RPh Pharmacy Times Postdoc researcher. Reproductive justice advocate. Toronto, Ontario | Safe Opioid Prescribing, Storage Are Crucial - 4 months ago | |
| 8 | Shannon Firth MedPage Today Washington correspondent for MedPageToday. CUNYJschool pride. | No Survival Benefit to Higher Intranasal Naloxone Dose - 11 months ago Adding Nurse Care Managers in Primary Care Boosted OUD Treatment - about 1 year ago | |
| 9 | John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California | ||
| 10 | Michael DePeau-Wilson MedPage Today Enterprise Reporter. AI in Healthcare focus. Journalism alum. Not specified |